← Leaderboards
Daniel W. Copeland
Renovion, Inc.
$895,696
Attributed
$1,791,392
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $920.8K · FY2020–21$1M$750K$500K$250K$0
'20
'21
Funding mix
By agency
NIH$1,791,392 · 1
By mechanism
R44$1,791,392 · 1
Top collaborators
- Carolyn Durham2 shared
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAscorbic AcidAuthorization DocumentationAwarenessBacteriaBilateralBronchiectasisBronchiolitis ObliteransCaringCessation Of LifeChronicChronic Lung DiseaseChronic Obstructive Airway DiseaseClinical DataClinical PracticeClinical ResearchClinical Trials Data Monitoring CommitteesCommercializationControl GroupsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDesignDisease ProgressionAdvanced Development